search
Back to results

Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?

Primary Purpose

Respiratory Complication, Morbid Obesity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Accelomyography
Neostigmine
Qualitative Monitor
Sponsored by
Coastal Anesthesiology Consultants
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Respiratory Complication focused on measuring residual muscle weakness, respiratory events

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- All patients scheduled for bariatric surgery at Flagler Hospital will be included after written and informed consent.

Exclusion Criteria:

- Patients will be excluded from the study if they don't consent to participate in the study. Patients allergic to any of the study medication will be excluded.

Sites / Locations

  • Flagler Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Control Group

Study Group

Arm Description

qualitative monitoring of neuromuscular paralysis, standard treatment at this facility

quantitative monitoring of neuromuscular paralysis as described in (Brull Murphy Anesth Analg 2010;111:129-40) Acceleromyography

Outcomes

Primary Outcome Measures

Respiratory Events (RE)
Definition of RE, adapted from Ziemann-Gimmel et. al. f1000research 2012 and Murphy et. al. Anesth Analg 2010;107(1):130-7 Upper airway obstruction requiring an intervention; Hypoxemia despite 3 l/min NC requiring any intervention increasing FiO2 greater than 3 l/min NC tactile stimulation Signs of respiratory distress or impending ventilatory failure; Patient complaining of symptoms of respiratory or upper airway muscle weakness; w or w/o intervention Patient requiring reintubation in the PACU diagnosis of pneumonia on discharge or administration of antibiotics for suspected aspiration pneumonia unplaned application of CPAP/BiPAP unplanned ICU admission for respiratory reasons hypercarbic respiratory failure bag mask ventilation administration of "rescue" reversal after extubation for clinically suspected weakness prolonged intubation and ventilation in PACU and/or in ICU unplanned administration of breathing treatment

Secondary Outcome Measures

Full Information

First Posted
January 14, 2014
Last Updated
February 4, 2016
Sponsor
Coastal Anesthesiology Consultants
search

1. Study Identification

Unique Protocol Identification Number
NCT02037516
Brief Title
Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?
Official Title
Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Coastal Anesthesiology Consultants

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine if residual weakness after weight loss surgery leads to an increased risk of respiratory complications in the postoperative period.
Detailed Description
Patients interested in bariatric surgery would contact Dr. Marema or Dr. Koppman. Dr. Marema and Dr. Koppman will determine, if patients qualify for bariatric surgery. Patients will undergo a thorough preoperative workup. After optimization of all medical conditions patients would be scheduled for bariatric surgery. This is our current clinical practice. One of the investigators would determine if a patient would qualify for the study. Then one of the investigators would approach the patients and explain the study in detail. Patients would be able to give informed consent or refuse to participate. Patients refusing to participate in the study will need to sign a consent that data will be collect for internal quality control (IRB approval on file). The patients would be scheduled for bariatric surgery and be treated per our current clinical practice. All patients would undergo a similar anesthetic. At the end of the procedure, before the NMBA reversal agent is given, the patients would be randomized to either the control or study group. Intraoperative Anesthestic Management: Patients receive sedative medication, typically midazolam 2-4mg iv. An infusion of dexmedetomidine will be started. Patients younger than 65 years will receive a loading dose of 1mcg/kg over 10 minutes. In patients older than 65 years 0.5 mcg/kg will be given as a loading dose. After administration of the loading dose an infusion will be continued throughout the duration of the surgery at a dose of 0.1-1mcg/kg/h. The infusion will be discontinued at the end of surgery. General anesthesia will be induced with a single dose of Lidocaine and Propofol with either Succinylcholine or Rocuronium given to provide intubating conditions. The patient's trachea will be intubated and mechanical ventilation started. General anesthesia will be maintained with an infusion of dexmedetomidine and propofol and titrated to the desired level of anesthesia. Ketamine will be administered as an adjunctive analgesic at a dose of 0.5 mg/kg. Neuromuscular blockade appropriate for surgical conditions will be provided by either the long acting neuromuscular blocking agents (NMBA), Rocuronium or Vecuronium, at the anesthesia providers discretion. At the conclusion of the operation the degree of NMB/paralysis will be assessed and a NMBA reversal administered (see detailed description below). Patients will be extubated after the end of surgery and transported to the PACU. Monitoring of Neuro-Muscular Block (NMB or paralysis): A signal is send from the brain to the muscle via an electrical impulse through a nerve. Electrical impulses can be applied externally to provoke muscle contraction. This technique is used to monitor the degree of paralysis induced by administration of NMBA. NMBAs interrupt impulses or signals from the nerve to the muscle. External stimulation also does NOT lead to a muscle contraction in a paralyzed patient. Once the body metabolizes the NMBA the signal can travel again from the nerve to the muscle and provoke a muscle twitch. This recovery is gradual meaning that the initial twitches are weak and gradually get stronger. Also muscle fatigue faster with NMBA present (fade). This means that with similar, repetitive stimulation the twitch gets weaker. In anesthesia these attributes are examined to determine the degree of muscle relaxation and, or if at all, a dose of NMBA reversal can be given and what the appropriate dose should be. There are two different ways of monitoring NMB: qualitative and quantitative. Qualitative (current management) - Control Group: The paralysis can be monitored tactile (feeling) or visual (seeing) to determine the twitch strength and the fade of repetitive stimulation. This determines the dose of reversal. After the reversal is given the anesthesia provider waits further to determine that the twitches are strong and there is no more fade. Then the patient will be extubated and transported to the PACU. Quantitative (proposed management) - Study Group: The paralysis would be monitored with a sensor (acceleromyography - AMG) that measures the twitch-strength after the ulnar nerve was stimulated (detailed explanation below). This objective data allows the anesthesia provider to titrate the NMBA reversal to best effect to assure adequate return to full muscle strength. Then the patient will be extubated and transported to the PACU. AMG: The technical term for the way of assessing the muscle contraction is called acceleromyography (AMG). AMG relies on 2 stimulating electrodes usually placed along the ulnar nerve at the wrist and a sensor that is placed in the groove between the thumb and the index finger; the sensor detects the acceleration of movement (bending) that is produced by the thumb in response to electrical stimulation of the ulnar nerve (TOF-Watch® SX Monitor). When the thumb contracts and accelerates the piezoelectric sensor, the degree of movement is sensed, and it is converted into electrical signals that are proportional to the force of thumb contraction. AMG can yield signals that can be measured and that can give an indication of the degree of neuromuscular block. Randomization: Patients will be randomized at the time when NMB can be reversed. Depending on the result the patient will be in the study or control group. Randomization will be done by a statistical software called R or an online web program called random.org. Power analysis: reduction from risk of a respiratory event in the postoperative period from 30% to 17.5% with an alpha of 0.05 and a power of 0.8 allocation approximately even in both groups (n1=n2) total sample size n=362, critical z=1.96, calculated by G Power 3 Data analysis: primary Intention to treat analysis to reflect clinical reality, secondary analysis as per protocol Definition of RE, adapted from Ziemann-Gimmel et. al. f1000research 2012 and Murphy et. al. Anesth Analg 2010;107(1):130-7 Protocol Changes: Randomization occurs as described above at the time when the anesthesia provider feels "comfortable" based on the qualitative measurement of the TOF. If patient is randomized to the intervention group (quantitative measurement) reversal will be given based on the AMG (TOF Watch). The change to the protocol: If 30 minutes after the above time point no adequate AMG measurement is obtained reversal will be administered. If after administration of reversal 30 minutes have elapsed and the AMG is less than 90% patients will be emerged from anesthesia. administration of reversal in the intervention group will occur only after at least 4 twitches are measured consistently with the AMG. The previous suggested time-point suggested by the review article by Brull and Murphy where it can be given after 3 twitches seems to be to early and patients may not regain a TOF greater than 90%. Dealing with missing TOF data: If patients were randomized they will be analyzed in the according group (ITT). linear regression after log transformation will be done with the existing traces. There will be a best-/worst case scenario for sensitivity analysis. Missing values will be randomly sample and five scenarios will be analyzed to determine any impact (sensitivity analysis). (Imputation) Also the best/worst case scenario will be analyzed: best case: patients regain a TOF of 100% worst case: TOF is reduced by 5% from last measurement - it is physiologically unlikely that the TOF will be reduced to a greater extend over time.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Complication, Morbid Obesity
Keywords
residual muscle weakness, respiratory events

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
330 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control Group
Arm Type
Active Comparator
Arm Description
qualitative monitoring of neuromuscular paralysis, standard treatment at this facility
Arm Title
Study Group
Arm Type
Active Comparator
Arm Description
quantitative monitoring of neuromuscular paralysis as described in (Brull Murphy Anesth Analg 2010;111:129-40) Acceleromyography
Intervention Type
Device
Intervention Name(s)
Accelomyography
Other Intervention Name(s)
TOF watch
Intervention Description
quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
Intervention Type
Drug
Intervention Name(s)
Neostigmine
Intervention Description
Neostigmine is used to reverse the effects of neuromuscular blocking agents
Intervention Type
Device
Intervention Name(s)
Qualitative Monitor
Intervention Description
Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
Primary Outcome Measure Information:
Title
Respiratory Events (RE)
Description
Definition of RE, adapted from Ziemann-Gimmel et. al. f1000research 2012 and Murphy et. al. Anesth Analg 2010;107(1):130-7 Upper airway obstruction requiring an intervention; Hypoxemia despite 3 l/min NC requiring any intervention increasing FiO2 greater than 3 l/min NC tactile stimulation Signs of respiratory distress or impending ventilatory failure; Patient complaining of symptoms of respiratory or upper airway muscle weakness; w or w/o intervention Patient requiring reintubation in the PACU diagnosis of pneumonia on discharge or administration of antibiotics for suspected aspiration pneumonia unplaned application of CPAP/BiPAP unplanned ICU admission for respiratory reasons hypercarbic respiratory failure bag mask ventilation administration of "rescue" reversal after extubation for clinically suspected weakness prolonged intubation and ventilation in PACU and/or in ICU unplanned administration of breathing treatment
Time Frame
2 years

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - All patients scheduled for bariatric surgery at Flagler Hospital will be included after written and informed consent. Exclusion Criteria: - Patients will be excluded from the study if they don't consent to participate in the study. Patients allergic to any of the study medication will be excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Ziemann-Gimmel, MD
Organizational Affiliation
Coastal Anesthesiology Consultants
Official's Role
Principal Investigator
Facility Information:
Facility Name
Flagler Hospital
City
St. Augustine
State/Province
Florida
ZIP/Postal Code
32086
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?

We'll reach out to this number within 24 hrs